

Sartorius, Repligen to introduce Next-Gen perfusion-enabled bioreactors

05 September 2018 | News

Development collaboration integrates Sartorius Stedim Biotech's BIOSTAT® STR bioreactors and Repligen's XCell™ ATF cell retention control technology.



Sartorius Stedim Biotech, a leading international supplier for the biopharmaceutical industry, and Repligen Corporation, a global life sciences company focused on bioprocessing technologies, have entered into a collaboration agreement to integrate Repligen's XCell™ ATF cell retention control technology into SSB's BIOSTAT® STR large-scale single-use bioreactors to create novel perfusion-enabled bioreactors. As a result of this collaboration, end users will stand to benefit from a single control system for 50 L to 2,000 L bioreactors used in perfusion cell culture applications. This single interface is designed to control cell growth, fluid management and cell retention in continuous and intensified bioprocessing and, ultimately, simplify the development and cGMP manufacture of biological drugs.

Through the partnership, Sartorius Stedim Biotech and Repligen will further collaborate to equip SSB's recently launched ambr® 250ht perfusion single-use mini bioreactor system with Repligen's KrosFlo® hollow fiber filter technology. The bioreactor system will be sold by SSB as a complete single-use assembly. This optimal design conserves hollow fiber filter technology across scales, enabling customers to fast track development and scale up their cell culture perfusion processes.

"Sartorius Stedim Biotech has continuously expanded its integrated upstream portfolio over the past years with a focus on robust and scalable, automated single-use solutions, optimized for high-cell-density applications. The collaboration with Repligen will result in easy-to-implement, high-performance and perfusion-ready bioreactors ranging from process

development to commercial manufacturing scale,” commented Stefan Schlack, Head of Marketing at SSB.

Christine Gebski, Vice President of Product Management at Repligen, stated, “We are excited to partner with Sartorius Stedim Biotech, a global innovator in bioreactor technology. The integration of our market-leading XCell™ ATF control technology with SSB’s high-performance bioreactors offers a simplified perfusion-enabled bioreactor solution for end users to develop cell culture processes more quickly and implement perfusion more efficiently.”